Brought to you by 
Amgen, Kite Pharma partner in immunotherapies for cancer
22 Sep 2017
Executive Summary
Amgen Inc. and Kite Pharma Inc. are partnering to develop and commercialize next-generation chimeric antigen receptor T-cell (CART) immunotherapies combining targets from Amgen combined with Kite’s engineered Autologous Cell Therapy (eACT) platform.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen, Kite Pharma partner in immunotherapies for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice